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Abstract
Background: Left ventricular remodeling (LVR), an increase in left ventricular end-diastolic
volume index ≥ 20%, is an adverse consequence of myocardial infarction. The aim of this
study was to assess the association between LVR and adiponectin, which has been shown to
protect against myocardial ischemia-reperfusion injury.
Methods: In 75 patients echocardiographic examination was performed one year after
ST-segment elevation myocardial infarction, successfully treated with primary percutaneous
coronary intervention (pPCI). Two groups of patients were analyzed: those with LVR (n = 15)
and those without LVR (n = 60).
Results: The predictors of LVR were: anterior myocardial infarction, glucose at admission,
baseline C-reactive protein, adiponectin, and echocardiographic parameters: left ventricular
end-diastolic and end-systolic volume indices, ejection fraction < 40% and left ventricular
wall motion score index (WMSI) at discharge. On multivariable regression analysis, lower
adiponectin level (OR = 0.67, 95% CI 0.49–0.91, p < 0.05) and higher WMSI (OR = 20.14,
95% CI 2.62–154.82, p < 0.01) were the only independent negative predictors of LVR. The
optimal cut-off for adiponectin for predicting LVR was £ 4.7 mg/mL (sensitivity: 73%,
specificity: 85%) and this level increased the risk of LVR 15-fold (95% CI 4.05–59.87,
p = 0.0001).
Conclusions: Baseline low blood adiponectin concentration, along with WMSI, can be consi-
dered as a predictor of the LVR in male patients one year after myocardial infarction and pPCI.
(Cardiol J 2010; 17, 1: 49–56)
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Introduction
Left ventricular remodeling (LVR) after myo-
cardial infarction (MI) is a dynamic process result-
ing in global enlargement, changes in geometry and
mass of the left ventricle. Remodeling is an impor-
tant determinant of subsequent heart failure:
a major source of morbidity and mortality in the
post-infarction population. This adverse conse-
quence occurs in response to the loss of myocar-
dium and sudden increase in ventricular loading
conditions, subsequent infarct extension and late
hypertrophy in the remote ventricular myocardium
[1, 2]. Opening of the infarct-related artery is cru-
cial in the prevention of the LVR [3–5], but several
other important factors have been recognized.
These are infarct size, anterior location, microvas-
cular dysfunction, mitral regurgitation after MI, con-
tractile reserve and inducible ischaemia [6–11]. The
association between inflammation [12] and stress
hyperglycaemia [13, 14] on the remodeling process
have attracted attention recently.
Adiponectin, an adipose tissue-derived hor-
mone that is down-regulated in obese individuals,
affects several signaling pathways in skeletal mus-
cles, liver, cardiac myocytes and vascular cells [15].
Adiponectin has a favorable effect on endothelial
function and angiogenesis [16, 17] and suppresses
the atherogenic process [18, 19]. Several studies
suggest that adiponectin has anti-inflammatory
properties [20, 21], reduces endothelial cell apop-
tosis [22] and promotes nitric oxide production [23].
The protective action of adiponectin against myo-
cardial ischemia-reperfusion injury has been shown
recently [24, 25]. The value of adiponectin as a prog-
nostic factor of left ventricular function [26] and
future adverse cardiac events [27] after MI has been
recently suggested. To our knowledge, the associ-
ation between blood adiponectin concentration and
LVR following MI has not been analyzed.
The aim of the study was to assess the impact
of adiponectin on the LVR one year after acute MI




From the group of patients with the first
ST-segment elevation MI, successfully treated with
pPCI, 80 men aged £ 65 years were initially select-
ed for the study. Successful PCI was defined as the
restoration of TIMI 3 grade flow and residual ste-
nosis < 30% at the end of the procedure. In 99% of
patients, bare metal stents were implanted. Signi-
ficant valvular heart disease, atrial fibrillation, atrio-
ventricular block, temporary or permanent stimu-
lation, acute and chronic inflammation or infection,
autoimmune diseases, liver kidney and thyroid dis-
eases were considered as grounds for exclusion.
In 68% of patients, glycoprotein IIb/IIIa inhib-
itor was administered in the course of MI. In pa-
tients with multivessel disease, staged PCI of an-
other significant lesion was performed according to
agreement reached by the cardiologist and the in-
terventional cardiologist on an individual basis. The
pharmacological treatment according to the current
standards was recommended at discharge (aspirin,
clopidogrel for at least 30 days and statins in 100%
of patients, beta-blockers in 94% of patients, and
angiotensin converting enzyme-inhibitors in 66% of
patients).
At one year follow-up (12±1.2 months) we had
lost contact with one patient, two patients had died
and two patients had experienced subsequent MI.
In the other 75 patients who formed the study group
echocardiographic examination was performed. An
increase in left ventricular end-diastolic volume in-
dex (LVEDVI) ≥ 20% was accepted as a surrogate
for remodeling. The data was finally analyzed in
groups of patients divided into those with LVR
(n = 15; 20%) and those without LVR (n = 60; 80%).
Echocardiographic examination
Echocardiographic study was performed on the
second or third day after admission with Sonos
5500, S3 probe. The harmonic option was used to
enhance the visualization of the endocardium.
LVEDV, left ventricular end-systolic volume
(LVESV) and left ventricular ejection fraction
(LVEF) was assessed at four-chamber and two-
-chamber apical views with the biplane Simpson’s
formula. Left ventricular volumes indexed by body
surface area (LVEDVI, LVESVI) were calculated.
Impaired systolic function was diagnosed in cases
of LVEF below 40%. For each segment of LV, wall
motion was scored from one (normal) to four (dys-
kinetic) and global wall motion score index (WMSI)
was calculated as the average over 16 segments.
From the pulse-wave Doppler mitral inflow tracings
recorded from the four-chamber apical view the
following parameters were measured: early (E), and
late (A) transmitral peak flow velocities, E/A ratio
and E wave deceleration time (DT).
Laboratory measurements
Fasting blood samples for measurements of
adiponectin were taken on the next day after ad-
51
Katarzyna Piestrzeniewicz et al., Adiponectin predicts left ventricular remodeling after MI
www.cardiologyjournal.org
mission for ST elevation myocardial infarction. Plas-
ma for measurements was frozen at –70° until ana-
lysis with the quantitative sandwich enzyme immu-
noassay technique (ELISA) obtained from R&D
Systems Inc. Plasma triglicerydes (TG) and total
cholesterol (TCH) were measured by enzymatic
analytical chemistry. HDL-cholesterol (HDL-CH)
was precipitated using dextran-sulphate and meas-
ured enzymatically. The LDL-cholesterol (LDL-CH)
was calculated using the Friedewald equation:
LDL-CH = TCH – (TG/5) – HDL-CH. Hyperlipi-
demia was diagnosed in case of hypercholestero-
lemia (TCH > 200 mg/dL) with LDL-CH (LDL >
> 100 mg/dL) and/or hypertriglicerydemia (TG >
> 150 mg/dL) and low HDL-CH (HDL-CH <
< 40 mg/dL).
Statistical analysis
Continuous variables were presented as mean ±
± standard deviation. Variables were log-trans-
formed before statistical analysis if necessary. Com-
parisons between analyzed groups (with LVR and
without LVR) were performed using the two-tailed,
non-paired Student t test or Mann-Whitney test, as
appropriate. Differences in echocardiographic var-
iables at baseline and at one-year follow-up were
assessed with the paired Student’s t test. Catego-
rical data were summarized as frequencies and per-
centages, and comparisons between the groups
were performed with c2 test or Fisher’s exact test.
The independent predictors of LVR were assessed
using the multivariate logistic regression analysis,
including variables that were significantly associat-
ed with LVR in univariate analysis. The variables
included in the univariate logistic regression analy-
sis were: age, smoking, obesity, diabetes mellitus,
hypertension, dyslipidemia, time since the onset of
symptoms to admission, anterior myocardial infarc-
tion, multivessel disease, glucose at admission, be-
seline blood levels of adiponectin and C-reactive pro-
tein (CRP), baseline LVEDVI, LVESVI, LVEF <  40%,
WMSI, E/A and DT. Results were expressed as odds
ratio (OR) and confidence interval (CI). A receiver-
operating characteristics (ROC) curve analysis was
used to determine the cut-off values for adiponectin
for predicting LVR. P value < 0.05 was considered
statistically significant. Statistical analysis was per-
formed using Statistica software (version 6.0; Tul-
sa, OK, USA) and MedCalc statistical software (ver-
sion 7.2.1.0 for Windows; Mariakerke, Belgium).
The study was approved by the Internal
Ethics Committee of the Medical University of
Łódź, and each patient gave informed consent.
Results
Baseline clinical, biochemical, angiographic and
echocardiographic characteristics are presented in
Table 1. In the group with remodeling, the number
of patients with anterior localization of MI, glucose
at admission and beseline levels of CRP were sig-
nificantly higher and adiponectin concentration low-
er than in the group without remodeling.
Mean values of several echocardiographic pa-
rameters measured at baseline and at one year fol-
low-up differed between the analyzed groups:
LVEDVI, LVESVI, LVEF and WMSI were signifi-
cantly higher in patients with LVR. Systolic dys-
function (LVEF < 40%) was detected in more pa-
tients in this group (Table 2).
Table 1. Baseline characteristics of the study groups.
With remodeling Without remodeling p
(n = 15) (n = 60)
Age (years) 55 ± 5 54 ± 6 NS
Hypertension 9 (60%) 30 (50%) NS
Diabetes mellitus 5 (33%) 12 (20%) NS
Dyslipidemia 14 (93%) 46 (77%) NS
Obesity 7 (46%) 27 (45%) Ns
Smoking 11 (73%) 37 (62%) NS
Time since the onset of symptoms to admission [h] 5.0 ± 2.4 4.3 ± 2.8 NS
Anterior infarct localization 10 (67%) 22 (37%) < 0.05
Multivessel disease 6 (40%) 23 (38%) NS
Glucose at admission [mg/dL] 166.5 ± 49.7 128.0 ± 34.1 < 0.0001
C-reactive protein [mg/dL] 9.7 ± 6.8 5.1 ± 4.7 < 0.01
Adiponectin [mg/mL] 4.6 ± 2.2 10.1 ± 6.6 < 0.0001
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In univariate logistic regression analysis, pre-
dictors of LVR were: anterior myocardial infarction,
glucose at admission, beseline blood levels of adi-
ponectin and CRP, baseline LVEDVI, LVESVI,
LVEF < 40% and WMSI. The final model of multi-
variable regression analysis demonstrated that low-
er adiponectin levels and higher WMSI were the
independent negative predictors of LVR (Table 3).
Figure 1 shows the area under the ROC curves
for adiponectin concentration for predicting LVR
(AUC = 0.842; 95% CI = 0.740–0.916). The opti-
mal value of adiponectin for predicting LVR was
defined as the concentration with the largest sum
of sensitivity plus specificity for each of the curve.
The optimal cut-off for adiponectin was £ 4.7 mg/mL;
the sensitivity and specificity were 73% and 85%,
respectively.
LVEDVI, LVESVI, LVEF and WMSI signifi-
cantly differed between the group of patients with
blood adiponectin level £ 4.7 mg/mL (20 patients)
and > 4.7 mg/mL (55 patients) both at baseline (58 ±
± 11 vs 48 ± 11; 27 ± 10 vs 21 ± 7; 50 ± 10 vs 57 ±
± 9; 1.69 ± 0.43 vs 1.33 ± 0.31, respectively) and
at follow up (65 ± 11 vs 49 ± 12; 30 ± 11 vs 22 ± 8;
51 ± 11 vs 58 ± 9; 1.65 ± 0.45 vs 1.26 ± 0.27,
respectively). LVEDVI significantly increased from
baseline until the follow-up only in the group of
patients with blood adiponectin level £ 4.7 mg/mL
and WMSI significantly decreased at follow-up in
both groups (Fig. 2A–F). Blood adiponectin level
below 4.7 mg/mL 15.5-fold increased the risk of LVR
(95% CI 4.05–59.87, p = 0.0001).
Discussion
At present, despite the introduction of pPCI
into the treatment of MI and recommended wide-
spread use of ’anti-remodeling‘ medications, LVR
remains an important late complication. It is relat-
ed to microvascular dysfunction and the no-reflow
phenomenon within the risk area [11, 28] and with
the reduced coronary flow reserve [29].
The most interesting finding of our study is that
low baseline blood adiponectin concentration is an
independent predictor of the LVR after MI. The
efficacy of adiponectin as a prognostic factor of left
ventricular function following successful reper-
fusion has been shown by Shibata et al. [30]. These
authors, using the scintigraphic imaging, have re-
vealed that adiponectin levels were negatively as-
sociated with changes in LVEF at six months ob-
servation. This finding, together with the detected
association of adiponectin with myocardial salvage
parameters, inclined the authors to suggest that
adiponectin could be indicative of long-term myo-
cardial remodeling after MI. Our study confirms this
suggestion in a one year follow-up. There are se-
veral potential explanations of the protective func-
tion of adiponectin. The possible molecular mecha-
nisms mediating metabolic and vascular activity of
Table 2. Echocardiographic parameters at baseline and at one year follow-up in the study groups.
With remodeling Without remodeling p
(n = 15) (n = 60)
Baseline
LVEDVI [mL/m2] 57 ± 14 50 ± 11 < 0.05
LVESVI [mL/m2] 27 ± 11 22 ± 7 < 0.05
LVEF (%) 46 ± 8 58 ± 9 < 0.0001
LVEF < 40% — number of patients (%) 4 (27%) 1 (2%) < 0.001
WMSI 1.81 ± 0.39 1.33 ± 0.31 < 0.0001
E/A 1.09 ± 0.31 1.01 ± 0.29 NS
DT [ms] 195 ± 41 202 ± 38 NS
One-year follow-up
LVEDVI [mL/m2] 70 ± 15 49 ± 12 < 0.0001
LVESVI [mL/m2] 30 ± 12 22 ± 8 < 0.01
LVEF (%) 44 ± 9 59 ± 8 < 0.0001
WMSI 1.79 ± 0.40 1.26 ± 0.27 < 0.0001
E/A 1.00 ± 0.35 1.03 ± 0.28 NS
DT [ms] 226 ± 48 212 ± 42 NS
LVEDVI — left ventricular end-diastolic volume index; LVESVI — left ventricular end-systolic volume index; LVEF — left ventricular ejection fraction;
WMSI — wall motion score index; DT — deceleration time
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adiponectin involve stimulation of AMP kinase ac-
tivity and cyclooxygenase (COX)-2-dependent syn-
thesis of prostaglandin E2 that inhibits TNF-alpha
production [20, 24].
Experimental studies by Tao et al. [25] dem-
onstrated that adiponectin protects against
ischemia/reperfusion injury by inhibition of nitric
oxide, superoxide and their cytotoxic reaction prod-
uct formation. In animal models, Shibata at al. [26]
showed that adiponectin administered into the cre-
ated myocardial zone suppressed cardiac hypertro-
phy and interstitial fibrosis, protected against my-
ocyte apoptosis and increased capillary density in
the infarct border zone that was associated with
decreased left ventricular dilatation and improved
left ventricular function.
In our study group, including relatively young
men with the first, mostly inferior MI, successful
treatment with pPCI remodeling was observed in
20% of patients. Some other studies performed on
comparable groups of patients show similar results
to ours [6, 31]. Savoye et al. [8] reported the inci-
Table 3. Univariate and multivariate logistic regression analysis for the predictors of left ventricular
remodeling.
Odds ratio –95% CI +95% CI p
Univariate logistic regression analysis
Age 1.0426 0.9490 1.1454 0.3851
Hypertension 1.5000 0.4748 4.7388 0.4896
Diabetes mellitus 2.0000 0.5753 6.9532 0.2756
Dyslipidemia 4.2609 0.5139 35.3265 0.1792
Obesity 1.0694 0.3438 3.3264 0.9077
Smoking 1.7095 0.4863 6.0096 0.4032
Time since the onset of symptoms to admission 1.0756 0.8906 1.2990 0.4491
Anterior infarct localization 3.4545 1.0456 11.4131 0.0420
Multivessel disease 1.0725 0.3373 3.4098 0.9056
C-reactive protein 1.1451 1.0373 1.2641 0.0072
Glucose at admission 1.0228 1.0080 1.0378 0.0024
Adiponectin 0.6252 0.4498 0.8414 0.0024
LVEDVI baseline 1.0521 1.0005 1.1062 0.0476
LVESVI baseline 1.0738 1.0050 1.1473 0.0351
LVEF < 40% baseline 21.4545 2.1858 210.5807 0.0085
WMSI baseline 23.0276 4.7862 164.1286 0.0002
E/A baseline 2.3322 0.3712 14.6518 0.3664
DT baseline 0.9948 0.9795 1.0104 0.5123
Multivariate logistic regression analysis
WMSI baseline 20.1389 2.6210 154.8126 0.0017
Adiponectin 0.6680 0.4889 0.9080 0.0098
LVEDVI — left ventricular end-diastolic volume index; LVESVI — left ventricular end-systolic volume index; LVEF — left ventricular ejection fraction;
WMSI — wall motion score index; DT — deceleration time; CI — confidence interval
Figure 1. ROC curve for adiponectin for predicting left
ventricular remodeling.
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Figure 2. Changes in echocardiographic parameters from baseline to follow-up in patients with blood adiponectin
level below and above the optimal cut-off value for predicting left ventricular remodeling: 4.7 mg/mL; A. Left ventricular
end-diastolic volume index (LVEDVI); B. Left ventricular end-systolic volume index (LVESVI); C. Left ventricular
ejection fraction (LVEF); D. Left ventricular wall motion score index (WMSI); E. Early (E) to late (A) transmitral peak
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dence of LVR in 31% of the study group including
exclusively patients with at least three akinetic left
ventricular segments at discharge. This observation
indicates that infarct size is an important determi-
nant of subsequent changes in left ventricular vol-
ume. Our results and some other previous studies
[8, 32, 33], which identify WMSI as an independent
predictor of remodeling, confirm such a notion.
However, in our study group the relation between
decreased LVEF below 40% and LVR was not con-
firmed in multivariate analysis, suggesting that LVR
is not related to the deterioration of global left ven-
tricular function. Similar results were shown by
Łoboz-Grudzień et al. [6] but disparate observations
come from papers [4, 32] published before the wide-
spread application of pPCI and abciximab, a protec-
tor against microvascular disfunction [34].
It has been shown that in patients with MI,
stress hyperglycemia may be related to the no-re-
flow phenomenon [35], reduce collateral flow to the
area at risk [36], abolish the effect of precondition-
ing [37] and result in high one-year mortality [38].
The interesting observation came from the study
of Carrabba et al. [39] who showed that more fre-
quent progression to heart failure in diabetics after
MI cannot be explained by a greater propensity for
LVR. Recently, a significant and independent im-
pact of stress hyperglycemia on LVR after MI has
been revealed in non-diabetic patients [13, 14]. This
observation was not confirmed in our study group,
quite possibly due to the inclusion of both diabetic
and non-diabetic patients, and a very small subset
of non-diabetic patients with hyperglycemia on ad-
mission. It has been shown in some other studies
that stress hyperglycemia is associated with a more
adverse outcome, expressed as an increased risk
of congestive heart failure and one-year mortality
only in non-diabetics [40].
Limitations of the study
Unfortunately we have not performed serial
measurements of adiponectin in the course of MI,
whereas plasma adiponectin concentrations decline
significantly at 24 hours compared to the concen-
trations on admission and remains relatively stable
only between 24 and 72 hours [41]. Moreover, we
have measured CRP levels at admission, not the
peak values which have been shown to predict LVR
[12]. We have not performed coronary angiography
at follow-up, so the condition of the infarct related
artery and the late potency of the implanted stents
is not known.
The results of our study concern only male pa-
tients, so the conclusions cannot be generalized for
the whole population as there are sex-related differ-
ences in plasma adiponectin concentration [42].
Long-term clinical studies in large number of
patients are warranted to fully elucidate the impact
of several factors on LVR and consider the action
of the cluster of these factors.
Conclusions
Baseline low blood adiponectin concentration,
along with WMSI, can be considered as a predictor
of LVR in male patients one year after MI and pPCI.
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